HIV治療薬市場レポート：薬剤クラス別、流通チャネル別、地域別、2024年～2032年

世界のHIV治療薬市場規模は2023年に317億米ドルに達しました。今後、IMARC Groupは、2032年には439億米ドルに達し、2024年から2032年にかけて3.6%の成長率（CAGR）を示すと予測しています。同市場は、HIV/AIDSに対する認識と予防努力の高まり、世界のHIV/AIDS蔓延の拡大、より効果的で利用しやすい抗レトロウイルス療法に焦点を当てた様々な研究開発の進行などにより、着実な成長を遂げています。

HIV治療薬市場分析：

市場の成長と規模世界のHIV治療薬市場は、近年着実な成長を遂げています。HIV/AIDSの有病率の増加と治療プログラムの拡大により、今後も成長が見込まれます。

技術の進歩：技術の進歩により、より強力で忍容性の高い抗レトロウイルス薬が開発されています。長時間作用型の注射薬などドラッグデリバリーの仕組みが改善されたことで、治療のアドヒアランスが向上しました。また、遠隔医療やモバイルヘルスアプリにより、患者の管理やモニタリングが強化されています。

産業への応用HIV治療薬市場は、世界中のHIV/AIDS患者に貢献しています。また、ハイリスク集団に対する曝露前予防薬（PrEP）などの予防治療にも応用されています。さらに、この業界は政府、NGO、ヘルスケアプロバイダーと協力し、薬やケアへのアクセスを確保しています。

地理的動向：サハラ以南のアフリカやアジアの一部のような有病率の高い地域が大きな需要を牽引しています。北米と欧州も、先進治療へのアクセスにより大きな市場を形成しています。また、ラテンアメリカやアジア太平洋の新興市場も成長を続けています。

競合情勢：同市場は、主要企業が技術革新、M&A（合併・買収）、世界展開に注力する激しい競争を特徴としています。これらの戦略は、製品ポートフォリオを強化し、特定の業界ニーズを満たし、進化する市場の課題に対処することを目的としています。

課題と機会：課題には、継続的な治療の必要性、薬剤耐性、一部の薬剤の高コストなどがあります。機会としては、より安価で入手しやすい医薬品の開発、予防活動の拡大、潜在的な治療法の研究などが挙げられます。

将来の展望機能的な治療法および長時間作用型の治療法を目指した研究が進行中であり、このキーワードの将来は有望です。薬や予防法へのアクセスを向上させることは、依然として世界の保健上の優先事項です。さらに、技術の進歩や治療プログラムの拡大により、市場の成長は続くと予想されます。

HIV治療薬市場動向：

HIV/AIDSの蔓延拡大

世界のHIV/AIDSの流行は依然として公衆衛生上の重大な問題であり、2021年現在、世界で約3,800万人がHIVとともに生活しています。この有病率の増加は、HIV治療薬の需要を直接的に牽引しています。特に予防対策へのアクセスが限られている地域で新たな感染者が出続ける中、効果的な治療オプションの必要性が高まっています。特にサハラ以南のアフリカとアジア・東欧の一部地域ではHIVの感染率が高いため、HIV治療の要である抗レトロウイルス療法（ART）の持続的な普及が必要です。

治療の進歩

近年、HIV治療レジメンが大きく進歩し、HIV治療薬市場の成長に寄与しています。複数の抗レトロウイルス薬を併用する高活性抗レトロウイルス療法（HAART）の開発は、HIV治療に革命をもたらしました。これらの進歩は、HIV治療薬の有効性を向上させただけでなく、副作用を減らし、患者のアドヒアランスと治療成績の向上につながった。インテグラーゼ阻害剤のような新しい薬剤クラスのイントロダクションや長時間作用型注射剤の開発により、治療選択肢はさらに拡大し、患者の多様なニーズや嗜好に対応できるようになった。

患者の意識向上

認知度と診断率の向上は、HIV治療薬市場を牽引する極めて重要な要素です。公衆衛生キャンペーンや教育的イニシアチブは、HIV/AIDSに対する理解を深め、偏見を減らし、より多くの人々が検査を受けるよう促しています。また、早期診断技術の向上もHIVの発見率を高め、治療を受ける人の増加に寄与しています。このような診断率の上昇と、特に有病率の高い地域でHIV検査を改善するための継続的な取り組みとが相まって、効果的なHIV治療薬への需要が高まり続けています。

併用療法への注目の高まり

併用療法はHIV治療の標準となっており、複数の抗レトロウイルス薬を使用することで有効性を高め、薬剤耐性を防止しています。合剤（FDC）の開発と承認により治療レジメンが簡素化され、アドヒアランスと患者の転帰が改善されました。製薬会社は、錠剤の負担軽減や患者のコンプライアンス向上など、単剤療法と比較していくつかの利点があるこれらの併用療法の開発にますます注力しています。医療従事者や患者の間で併用療法への嗜好が高まっていることが、HIV治療薬市場を牽引する重要な要因となっています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のHIV治療薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 価格分析
• 市場内訳：薬剤クラス別
• 市場内訳：流通チャネル別
• 市場内訳：地域別
• 市場予測
• SWOT分析
  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威
• バリューチェーン分析
  • 概要
  • 研究開発
  • 原材料調達
  • 製造
  • マーケティング
  • 流通
  • 最終用途
• ポーターのファイブフォース分析
  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第6章 市場内訳：薬剤クラス別

• ヌクレオシド逆転写酵素阻害剤
  • 市場動向
  • 市場予測
• マルチクラス複合製品
  • 市場動向
  • 市場予測
• プロテアーゼ阻害剤
  • 市場動向
  • 市場予測
• HIVインテグラーゼ鎖転移阻害剤
  • 市場動向
  • 市場予測
• 非ヌクレオシド系逆転写酵素阻害剤
  • 市場動向
  • 市場予測
• エントリー阻害剤-CCR5共受容体拮抗薬
  • 市場動向
  • 市場予測
• 融合阻害剤およびその他
  • 市場動向
  • 市場予測

第7章 市場内訳：流通チャネル別

• 病院薬局
  • 市場動向
  • 市場予測
• 小売薬局
  • 市場動向
  • 市場予測
• オンライン薬局
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第8章 市場内訳：地域別

• 北米
  • 市場動向
  • 市場予測
• 欧州
  • 市場動向
  • 市場予測
• アジア太平洋
  • 市場動向
  • 市場予測
• 中東・アフリカ
  • 市場動向
  • 市場予測
• ラテンアメリカ
  • 市場動向
  • 市場予測

第9章 HIV薬の製造プロセス

• 製品概要
• 原材料要件
• 製造プロセス
• 主要成功要因とリスク要因

第10章 競合情勢

• 市場構造
• 市場内訳：主要企業別
• 主要企業のプロファイル
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

List of Figures

• Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
• Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2023
• Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2023
• Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2023
• Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: HIV Drugs Industry: SWOT Analysis
• Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
• Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
• Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
• Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
• Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
• Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
• Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
• Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
• Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
• Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
• Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
• Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

• Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
• Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: HIV Drugs Manufacturing: Raw Material Requirements
• Table 6: Global: HIV Drugs Market: Competitive Structure
• Table 7: Global: HIV Drugs Market: Key Players

The global HIV drugs market size reached US$ 31.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032. The market is experiencing steady growth driven by the increasing awareness and prevention efforts, the growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

HIV Drugs Market Analysis:

Market Growth and Size: The global HIV drugs market has witnessed steady growth in recent years. It is expected to continue growing due to the increasing prevalence of HIV/AIDS and the expansion of treatment programs.

Technological Advancements: Technological advancements have led to the development of more potent and tolerable antiretroviral drugs. Improved drug delivery mechanisms, such as long-acting injectables, have increased treatment adherence. Besides, telemedicine and mobile health apps are enhancing patient management and monitoring.

Industry Applications: The HIV drugs market serves patients living with HIV/AIDS worldwide. It also has applications in preventive treatments, including pre-exposure prophylaxis (PrEP) for high-risk populations. Moreover, the industry collaborates with governments, NGOs, and healthcare providers to ensure access to medications and care.

Geographical Trends: High prevalence regions like sub-Saharan Africa and parts of Asia drive significant demand. North America and Europe also have substantial markets due to access to advanced treatments. Besides, emerging markets in Latin America and Asia-Pacific are witnessing growth.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. These strategies aim to enhance product portfolios, meet specific industry needs, and address the challenges of an evolving market.

Challenges and Opportunities: Challenges include the need for continuous treatment, drug resistance, and the high cost of some medications. Opportunities lie in developing more affordable and accessible drugs, expanding prevention efforts, and research into potential cures.

Future Outlook: The future of the HIV drugs market holds promise, with ongoing research aiming for a functional cure and long-acting therapies. Increased access to medications and prevention methods remains a global health priority. Moreover, market growth is expected to continue, driven by technological advancements and expanded treatment programs.

HIV Drugs Market Trends:

The growing prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences.

Increasing awareness among patients

Enhanced awareness and diagnostic rates are pivotal in driving the market for HIV drugs. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising focus on combination therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. The growing preference for combination therapies among healthcare providers and patients is a key factor driving the market for HIV drugs.

HIV Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors - CCR5 co-receptor antagonist, fusion inhibitors and others. According to the report, nucleoside reverse transcriptase inhibitors represented the largest segment.

NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Hospital pharmacies holds the largest share in the industry

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies and others. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America leads the market, accounting for the largest HIV drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

Leading Key Players in the HIV Drugs Industry:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

ViiV Healthcare

AbbVie

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Gilead Sciences, Inc.

Johnson & Johnson

Cipla Limited

Daiichi Sankyo

Emcure Pharmaceuticals

Hetero Drugs

Mylan N.V

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

2021: Merc received approval from the U.S. Food and Drug Administration (FDA) for its new antiretroviral drug, Isentress HD, which offers improved dosing convenience for patients. The introduction of ISENTRESS HD reflects Merck's commitment to innovation in HIV therapy, offering a broader range of treatment options to fit the individual needs and lifestyles of people living with HIV. The price of ISENTRESS HD is set to be the same as the twice-daily ISENTRESS, and it was anticipated to be available in pharmacies approximately four weeks following the approval announcement.

June 2022: Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for younger children. This innovative treatment has been approved by the South African Health Products Regulatory Authority (SAHPRA) and is specifically designed for infants and young children living with HIV.

In 2021: Johnson & Johnson has also been actively involved in the development of HIV drugs. In 2021, the company received FDA approval for its new antiretroviral drug, Rekambys, which is a long-acting injectable treatment option for HIV-1 infection in certain patients.

Key Questions Answered in This Report

• 1. What was the size of the global HIV drugs market in 2023?
• 2. What is the expected growth rate of the global HIV drugs market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global HIV drugs market?
• 4. What are the key factors driving the global HIV drugs market?
• 5. What is the breakup of the global HIV drugs market based on the drug class?
• 6. What is the breakup of the global HIV drugs market based on the distribution channel?
• 7. What are the key regions in the global HIV drugs market?
• 8. Who are the key players/companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global HIV Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Price Analysis
• 5.5 Market Breakup by Drug Class
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast
• 5.9 SWOT Analysis
  • 5.9.1 Overview
  • 5.9.2 Strengths
  • 5.9.3 Weaknesses
  • 5.9.4 Opportunities
  • 5.9.5 Threats
• 5.10 Value Chain Analysis
  • 5.10.1 Overview
  • 5.10.2 Research and Development
  • 5.10.3 Raw Material Procurement
  • 5.10.4 Manufacturing
  • 5.10.5 Marketing
  • 5.10.6 Distribution
  • 5.10.7 End-Use
• 5.11 Porters Five Forces Analysis
  • 5.11.1 Overview
  • 5.11.2 Bargaining Power of Buyers
  • 5.11.3 Bargaining Power of Suppliers
  • 5.11.4 Degree of Competition
  • 5.11.5 Threat of New Entrants
  • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

• 6.1 Nucleoside Reverse Transcriptase Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-Class Combination Products
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Protease Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 HIV Integrase Strand Transfer Inhibitors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Fusion Inhibitors and Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

• 9.1 Product Overview
• 9.2 Raw Material Requirements
• 9.3 Manufacturing Process
• 9.4 Key Success and Risk Factors

10 Competitive Landscape

• 10.1 Market Structure
• 10.2 Market Breakup by Key Players
• 10.3 Profiles of Key Players
  • 10.3.1 Boehringer Ingelheim International GmbH
  • 10.3.2 Merck & Co., Inc.
  • 10.3.3 ViiV Healthcare
  • 10.3.4 AbbVie
  • 10.3.5 F. Hoffmann-La Roche Ltd.
  • 10.3.6 Teva Pharmaceutical Industries Ltd.
  • 10.3.7 Bristol-Myers Squibb
  • 10.3.8 Gilead Sciences, Inc.
  • 10.3.9 Johnson & Johnson
  • 10.3.10 Cipla Limited
  • 10.3.11 Daiichi Sankyo
  • 10.3.12 Emcure
  • 10.3.13 Hetero Drugs
  • 10.3.14 Mylan